A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical Resection — SABRTOOTHv1

Oncology Clinical Trial

Official title:
A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy (SABR) With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer (NSCLC) cOnsidered Higher Risk of Complications From Surgical Resection

Status Completed

Clinical Trial Summary

Stage I non-small cell lung cancer (NSCLC) is curable and surgery is considered the standard of care for fit, good performance status patients. However, a high proportion of patients with stage 1 NSCLC are elderly and/or have medical co-morbidities and are therefore at higher risk of surgical complications. The optimal treatment for these patients is unknown. SABR may be an equally appropriate treatment but this need to be formally assessed. Funded by the NIHR Research for Patient Benefit, SABRtooth is a UK multi-centre, two-group individually randomised controlled feasibility study of patients with peripheral stage I non-small cell lung cancer considered at higher risk from surgery. In total, 54 patients are planned to be recruited from 4 treatment sites and 2 referral sites. This study aims to determine the feasibility and acceptability of performing a largescale definitive randomised phase III trial comparing surgery with stereotactic ablative radiotherapy (SABR). The qualitative substudy is an exploration of the reasons for nonparticipation in the SABRTooth trial. As the two treatments are very different, patients may have a strong preference for either surgery or SABR, or may feel uncomfortable to have a decision between such distinct options taken out of their hands. Understanding why patients choose not to participate or do not take up their treatment allocation will be crucial in demonstrating that recruiting to a larger scale phase III trial is feasible. We will explore what patients, who have declined particpation in the study or who intiailly consented but subsequently fail to take up their randomimsed treatment arm, understand, perceive and feel about, how the SABRTooth trial was presented to them and their expectations of study burden.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02629458
Study type	Interventional
Source	The Leeds Teaching Hospitals NHS Trust
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2015
Completion date	January 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01439152` - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05615246` - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting	`NCT06015009` - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers	N/A
Active, not recruiting	`NCT03298100` - Risk Scoring Model for Endometrial Cancer
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Not yet recruiting	`NCT04324320` - Psychological Distress in Outpatient Oncological Rehabilitation
Completed	`NCT00588289` - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA	N/A
Recruiting	`NCT06222801` - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting	`NCT03831633` - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients	Phase 4
Completed	`NCT04914702` - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting	`NCT05198570` - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting	`NCT05712174` - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT03832062` - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed	`NCT03988777` - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting	`NCT06031233` - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	Phase 4
Enrolling by invitation	`NCT04019119` - Digital Intervention for the Modification of Lifestyles (iGame)	N/A
Not yet recruiting	`NCT05926362` - Capillary-Venous Paired Data Collection
Recruiting	`NCT05686213` - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial	Phase 2
Recruiting	`NCT05510856` - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients	Phase 4
Completed	`NCT04180306` - PEWS Implementation in an LMIC Setting	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.